[go: up one dir, main page]

CY2016031I1 - Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων - Google Patents

Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Info

Publication number
CY2016031I1
CY2016031I1 CY2016031C CY2016031C CY2016031I1 CY 2016031 I1 CY2016031 I1 CY 2016031I1 CY 2016031 C CY2016031 C CY 2016031C CY 2016031 C CY2016031 C CY 2016031C CY 2016031 I1 CY2016031 I1 CY 2016031I1
Authority
CY
Cyprus
Prior art keywords
ivermectin
treatment
pharmaceutical form
topical pharmaceutical
dermatological conditions
Prior art date
Application number
CY2016031C
Other languages
English (en)
Other versions
CY2016031I2 (el
Original Assignee
Galderma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016031(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Galderma S.A. filed Critical Galderma S.A.
Publication of CY2016031I2 publication Critical patent/CY2016031I2/el
Publication of CY2016031I1 publication Critical patent/CY2016031I1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY2016031C 2003-04-24 2016-09-09 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων CY2016031I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Publications (2)

Publication Number Publication Date
CY2016031I2 CY2016031I2 (el) 2017-03-15
CY2016031I1 true CY2016031I1 (el) 2017-03-15

Family

ID=33312271

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100856T CY1111797T1 (el) 2003-04-24 2011-09-07 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY2016031C CY2016031I1 (el) 2003-04-24 2016-09-09 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100856T CY1111797T1 (el) 2003-04-24 2011-09-07 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων

Country Status (16)

Country Link
US (6) US7550440B2 (el)
EP (1) EP1620113B1 (el)
JP (2) JP5711867B2 (el)
KR (1) KR101187231B1 (el)
AU (1) AU2004231323C1 (el)
BR (1) BRPI0410503B8 (el)
CA (1) CA2522579C (el)
CY (2) CY1111797T1 (el)
FR (1) FR15C0069I2 (el)
HU (1) HUS1500048I1 (el)
LT (1) LTC1620113I2 (el)
LU (1) LU92915I2 (el)
MX (1) MXPA05011208A (el)
PL (2) PL378932A1 (el)
RU (1) RU2350333C3 (el)
WO (1) WO2004093886A1 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MXPA05011208A (es) * 2003-04-24 2005-12-14 Galderma Sa Uso de ivermectina para el tratamiento de desordenes dermatologicos.
BR0318319A (pt) * 2003-05-25 2006-07-18 Yuwan Wang métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
WO2008067054A2 (en) * 2006-10-12 2008-06-05 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
FR2907012B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
ES2719200T3 (es) * 2008-10-29 2019-07-09 Arbor Pharmaceuticals Llc Sistema conservante para formulaciones tópicas terapéuticas basadas en emulsión
EP2419082B1 (fr) * 2008-12-23 2020-01-22 Galderma S.A. Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
KR102428738B1 (ko) 2013-08-08 2022-08-02 노반, 인크. 국소 조성물 및 그의 사용 방법
JP6448641B2 (ja) * 2013-11-29 2019-01-09 ガルデルマ・ソシエテ・アノニム アトピー性皮膚炎の治療及び/又は予防のためのアベルメクチンファミリー又はミルベマイシンファミリーの化合物
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US20170232024A1 (en) * 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2017064206A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a composition comprising a high concentration of one or more avermectins
WO2017064205A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
RU2738932C2 (ru) * 2016-08-04 2020-12-18 Нестле Скин Хелт Са Композиции и их применение для лечения или профилактики розацеа
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
WO2018083196A1 (en) 2016-11-03 2018-05-11 Nestlé Skin Health Sa Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
CN110753549A (zh) * 2017-06-12 2020-02-04 莱克伍德阿美达克斯股份有限公司 双磷脂素凝胶制剂及其用途
US10835517B2 (en) 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
WO2020064843A1 (en) * 2018-09-28 2020-04-02 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
WO2020210784A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
AU2020333860A1 (en) * 2019-08-21 2022-04-07 Leo Pharma A/S Solvent delivery system for topical delivery of active agents
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
CA2473760C (en) * 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
EP1480633A2 (en) * 2002-03-04 2004-12-01 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
MXPA05011208A (es) * 2003-04-24 2005-12-14 Galderma Sa Uso de ivermectina para el tratamiento de desordenes dermatologicos.
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme

Also Published As

Publication number Publication date
RU2350333C2 (ru) 2009-03-27
PL1620113T3 (pl) 2011-10-31
US20090227668A1 (en) 2009-09-10
BRPI0410503A (pt) 2006-06-20
JP5538461B2 (ja) 2014-07-02
PL378932A1 (pl) 2006-06-12
US8093219B2 (en) 2012-01-10
WO2004093886A1 (en) 2004-11-04
JP2012126738A (ja) 2012-07-05
CY1111797T1 (el) 2015-10-07
LTC1620113I2 (lt) 2018-02-26
US20060100165A1 (en) 2006-05-11
US20120258062A1 (en) 2012-10-11
JP5711867B2 (ja) 2015-05-07
US7550440B2 (en) 2009-06-23
AU2004231323B2 (en) 2009-12-10
CY2016031I2 (el) 2017-03-15
CA2522579A1 (en) 2004-11-04
JP2006524212A (ja) 2006-10-26
US8470788B2 (en) 2013-06-25
AU2004231323A1 (en) 2004-11-04
LU92915I2 (fr) 2016-02-17
MXPA05011208A (es) 2005-12-14
FR15C0069I2 (fr) 2016-04-22
KR101187231B1 (ko) 2012-10-02
KR20060004667A (ko) 2006-01-12
AU2004231323C1 (en) 2016-11-03
EP1620113B1 (en) 2011-07-13
FR15C0069I1 (el) 2015-12-04
US8598129B2 (en) 2013-12-03
BRPI0410503B1 (pt) 2018-07-10
BRPI0410503B8 (pt) 2021-05-25
US20120077766A1 (en) 2012-03-29
EP1620113A1 (en) 2006-02-01
RU2005136438A (ru) 2006-05-27
US20130209381A1 (en) 2013-08-15
RU2350333C3 (ru) 2018-08-24
US8415311B2 (en) 2013-04-09
US8080530B2 (en) 2011-12-20
US20090252797A1 (en) 2009-10-08
CA2522579C (en) 2012-08-28
HUS1500048I1 (hu) 2017-10-30

Similar Documents

Publication Publication Date Title
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
DK1620113T3 (da) Topisk formulering af ivermectin til behandling af dermatologiske lidelser
PT1485127E (pt) Administração de agentes para o tratamento de inflamação
ITMI20020756A1 (it) Composizioni farmaceutiche topiche per il trattamento delle dermatiti
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IL175535A (en) Compositions for treatment of neurodegenerative diseases
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
DE60335019D1 (de) Topische hautpräparate
DK1553950T3 (da) Terapeutisk behandling
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
IS8225A (is) 2-etoxý-3-fenýlprópíónsýruafleiður til að meðhöndla fitusjúkdóma
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
ITMI20022263A1 (it) Composizioni per il trattamento delle emorroidi.
SE0400575D0 (sv) A novel pharmacentical composition for the treatment of skin conditions
ITMI20020055A1 (it) Composizione medicinale per il trattamento della degenerazione artilaginea